Limits...
Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects.

Brouwer BA, de Greef BT, Hoeijmakers JG, Geerts M, van Kleef M, Merkies IS, Faber CG - Drugs Aging (2015)

Bottom Line: Over the last 10 years, the diagnosis small fiber neuropathy (SFN) has gained recognition worldwide.A substantial subset of patients with SFN is aged 65 years or older, and these patients often exhibit comorbidities and usage of multiple drugs, making neuropathic pain treatment more challenging.Possible pitfalls in neuropathic pain treatment in the elderly will be underlined.

View Article: PubMed Central - PubMed

Affiliation: Department of Anesthesiology and Pain Medicine, Maastricht University Medical Center, 6202 AZ, Maastricht, The Netherlands.

ABSTRACT
Over the last 10 years, the diagnosis small fiber neuropathy (SFN) has gained recognition worldwide. Patients often suffer from severe neuropathic pain that may be difficult to treat. A substantial subset of patients with SFN is aged 65 years or older, and these patients often exhibit comorbidities and usage of multiple drugs, making neuropathic pain treatment more challenging. In this review, we highlight relevant pathophysiological aspects and discuss currently used therapeutic strategies for neuropathic pain. Possible pitfalls in neuropathic pain treatment in the elderly will be underlined.

No MeSH data available.


Related in: MedlinePlus

Comorbidities and use of drugs in the elderly. a Number of comorbidities at initial presentation. b Number of drugs used at initial presentation in patients with SFN aged 65 years or older (n = 117). Concomitant disorders were hypertension (60 %), cardiovascular disease (44 %), immune-mediated diseases (20 %), malignancy (16 %) and diabetes mellitus (9 %). SFN small fiber neuropathy
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4548010&req=5

Fig1: Comorbidities and use of drugs in the elderly. a Number of comorbidities at initial presentation. b Number of drugs used at initial presentation in patients with SFN aged 65 years or older (n = 117). Concomitant disorders were hypertension (60 %), cardiovascular disease (44 %), immune-mediated diseases (20 %), malignancy (16 %) and diabetes mellitus (9 %). SFN small fiber neuropathy

Mentions: A substantial number of patients with SFN are 65 years or older. In our cohort of 598 patients diagnosed with SFN, diagnosed according to international criteria, at the Maastricht University Medical Center [2, 3], 19 % were 65 years or older (n = 117). Most of these elderly patients had several comorbidities at first presentation (Fig. 1a). Only 11 % (n = 13) had no comorbidity (compared with 46 % in patients <65 years; Χ2 test, p < 0.001). The most frequent concomitant disorders were hypertension (60 %), cardiovascular disease (44 %), immune-mediated diseases (20 %), malignancy (16 %) and diabetes mellitus (9 %). As a consequence, most patients used several drugs, on average four (Fig. 1b). Only 6 % did not use any medication (compared with 26 % in patients <65 years; Χ2 test, p < 0.001).Fig. 1


Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects.

Brouwer BA, de Greef BT, Hoeijmakers JG, Geerts M, van Kleef M, Merkies IS, Faber CG - Drugs Aging (2015)

Comorbidities and use of drugs in the elderly. a Number of comorbidities at initial presentation. b Number of drugs used at initial presentation in patients with SFN aged 65 years or older (n = 117). Concomitant disorders were hypertension (60 %), cardiovascular disease (44 %), immune-mediated diseases (20 %), malignancy (16 %) and diabetes mellitus (9 %). SFN small fiber neuropathy
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4548010&req=5

Fig1: Comorbidities and use of drugs in the elderly. a Number of comorbidities at initial presentation. b Number of drugs used at initial presentation in patients with SFN aged 65 years or older (n = 117). Concomitant disorders were hypertension (60 %), cardiovascular disease (44 %), immune-mediated diseases (20 %), malignancy (16 %) and diabetes mellitus (9 %). SFN small fiber neuropathy
Mentions: A substantial number of patients with SFN are 65 years or older. In our cohort of 598 patients diagnosed with SFN, diagnosed according to international criteria, at the Maastricht University Medical Center [2, 3], 19 % were 65 years or older (n = 117). Most of these elderly patients had several comorbidities at first presentation (Fig. 1a). Only 11 % (n = 13) had no comorbidity (compared with 46 % in patients <65 years; Χ2 test, p < 0.001). The most frequent concomitant disorders were hypertension (60 %), cardiovascular disease (44 %), immune-mediated diseases (20 %), malignancy (16 %) and diabetes mellitus (9 %). As a consequence, most patients used several drugs, on average four (Fig. 1b). Only 6 % did not use any medication (compared with 26 % in patients <65 years; Χ2 test, p < 0.001).Fig. 1

Bottom Line: Over the last 10 years, the diagnosis small fiber neuropathy (SFN) has gained recognition worldwide.A substantial subset of patients with SFN is aged 65 years or older, and these patients often exhibit comorbidities and usage of multiple drugs, making neuropathic pain treatment more challenging.Possible pitfalls in neuropathic pain treatment in the elderly will be underlined.

View Article: PubMed Central - PubMed

Affiliation: Department of Anesthesiology and Pain Medicine, Maastricht University Medical Center, 6202 AZ, Maastricht, The Netherlands.

ABSTRACT
Over the last 10 years, the diagnosis small fiber neuropathy (SFN) has gained recognition worldwide. Patients often suffer from severe neuropathic pain that may be difficult to treat. A substantial subset of patients with SFN is aged 65 years or older, and these patients often exhibit comorbidities and usage of multiple drugs, making neuropathic pain treatment more challenging. In this review, we highlight relevant pathophysiological aspects and discuss currently used therapeutic strategies for neuropathic pain. Possible pitfalls in neuropathic pain treatment in the elderly will be underlined.

No MeSH data available.


Related in: MedlinePlus